4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Lee's Pharmaceutical Holdings Limited (0950) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Sha Tin, Hong Kong with about 1,137 employees. Its market capitalization is roughly HK$698 million. In the fiscal year ended 2025-12-31, 0950 reported HK$1.4B in revenue and HK$92M in net income.
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
Interactive charts & full statements → Open the 0950 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | HK$1.4B | HK$1.4B | HK$1.1B | HK$1.2B | — |
| Gross Profit | HK$730M | HK$753M | HK$551M | HK$771M | — |
| Operating Income (EBIT) | HK$76M | HK$77M | (HK$7M) | HK$76M | — |
| Net Income | HK$92M | HK$93M | HK$17M | HK$51M | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dividends Paid | (HK$28M) | (HK$18M) | (HK$11M) | (HK$24M) | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | HK$3.5B | HK$2.6B | HK$2.9B | HK$2.8B | — |
| Total Liabilities | HK$1.6B | HK$1.1B | HK$930M | HK$940M | — |
HKD; HK$M / HK$B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 0950 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms